ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.

Legacy IAM can't govern autonomous AI agents that spin up, execute and terminate in seconds. New identity patterns are now emerging. The post Why Traditional IAM Is No Match for Agentic AI appeared ...

I took a shot and I wrote an article to a scientific journal, and next thing you know, it went through the peer review ...

However, a new study warns that the same capabilities driving their adoption are also creating a broad and evolving landscape of security, privacy, and ethical risks that existing safeguards are ...

Joining us today is Panna Sharma, Chief Executive Officer, President and Director of Lantern Pharma, who will guide us through the demonstration and discuss the broader implications of this technology ...

Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery April 30, 2026 8:30 AM ...

At a Reuters conference earlier this year, Johnson & Johnson chief information officer Jim Swanson offered a striking number: ...

One garnishment is painful. Multiple could drain your paycheck. But can your creditors really dip in all at once?

Congress has approved another short-term extension of controversial spy powers that permit US officials to monitor phone ...

Get live updates and the latest news as the Supreme Court weighs Trump's effort to revoke TPS immigration protections and the ...

The human brain has the curious capacity to look for patterns without our full awareness, but we can utilize active, mindful ...

New strategic frameworks are emerging to help industries move AI adoption beyond isolated pilots, with engineering and asset management leaders rethinking workflows, talent, and operating models.